



## Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

## Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™

Dec 21 2020, 12:20 PM EST

## Abeona Therapeutics Reports Third Quarter Financial Results

Nov 9 2020, 4:05 PM EST

## Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer

Oct 27 2020, 6:30 AM EDT

## Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	210.85m
Last Price	\$2.14
52-Week	\$0.99 - \$4.35

01/19/2021 04:00 PM EST

## Investor Relations

[ir@abeonatherapeutics.com](mailto:ir@abeonatherapeutics.com)

## Management Team

### Michael Amoroso

Executive Vice President, Chief Operating Officer

### Jay Bircher

Chief Technical Officer

### Edward Carr

Chief Accounting Officer, Principal Financial Officer

### Jodie Gillon, M.P.H.

Vice President, Chief Patient Officer

### Greg Gin

Vice President, Investor Relations and Corporate Communications

### Kristina Maximenko

Vice President, Human Resources

### Scott Nogi

Vice President, Business Operations

### Brendan O'Malley, J.D., Ph.D.

Vice President, Head of Legal and IP

### Juan Ruiz, M.D., Ph.D.

Head of European Medical Affairs

---

## Abeona Therapeutics Inc.

1330 Avenue of the Americas  
33rd Floor  
New York, NY 10019

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.